drugset / Trial / NCT00626392

Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia

NCT00626392

Phase 3 Completed 277 enrolled Abbott
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of this study was to assess the effect of aspirin (ASA) on niacin extended-release (NER)-induced flushing in subjects with dyslipidemia.

Timeline

Start
2008-02
Primary completion
2008-04
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 325 mg Oral
Subject Niacin Small molecule 2000 mg

Indications